Impact of fractional CO2 laser therapy on vaginal wall histology in breast cancer survivors.
Sine Jacobsen, Mary Holten Bennetsen, Patricia Switten Nielsen...
https://pubmed.ncbi.nlm.nih.gov/41665827/Actively Recruiting
Led by University of Aarhus · Updated on 2024-12-05
60
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are evaluating vaginal CO2 laser therapy for genitourinary syndrome of menopause in breast cancer survivors who are undergoing endocrine therapy. This study involves three parts over three years, including a dose response study with 30 participants, a double-blind randomized controlled trial with 60 participants receiving either active or placebo laser treatment, and a one-year follow-up to assess long-term effects. The study is conducted at departments of obstetrics, gynecology, and oncology in collaboration at regional hospitals and a university hospital. Participants in the active laser group receive intravaginal treatment using the fractional microablative CO2 laser system with specific power and timing settings, while the sham group receives a placebo laser treatment with much lower power settings. The dose response study involves five treatments spaced 4-6 weeks apart, and the randomized trial involves three to five treatments every three weeks. The follow-up year monitors changes after treatment completion. During the study, participants will complete questionnaires and undergo assessments including vaginal fluid pH measurements, vaginal biopsies, and analyses of vaginal and urine microbiomes before and after each treatment. Researchers will measure symptoms such as vaginal dryness, pain, itching, soreness, sexual function, urinary symptoms, and vaginal health. These outcomes are evaluated at baseline and one month after the last treatment. The study includes safety monitoring and lasts until March 2026.
CONDITIONS
Vaginal CO2 Laser Therapy for Genitourinary Syndrome in Breast Cancer Survivors
S
Sine Jacobsen, MD
P
Pinar Bor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Aarhus
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Multiple treatment sessions over several weeks
Participants receive vaginal CO2 laser therapy or sham treatment using the fractional microablative CO2 laser system.
1 baseline visit and multiple treatment visits
Duration - 1 month after the last treatment
Participants are assessed for symptom improvement and vaginal health one month after the last treatment.
1 follow-up visit (in-person)
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sine Jacobsen, Mary Holten Bennetsen, Patricia Switten Nielsen...
https://pubmed.ncbi.nlm.nih.gov/41665827/Sine Jacobsen, Marianne Glavind-Kristensen, Anders Bonde Jensen...
https://pubmed.ncbi.nlm.nih.gov/38031020/University of Aarhus
Lead Sponsor